Ascendis Pharama

Photo of boy swimming forward: we are working to make a difference for patients with rare endocrine diseases and cancer

COMMITTED TO Making a meaningful difference for patients

Explore our technology

With TransCon® technology, this is just the start

Our powerful technology platform—combined with a unique algorithm for sustainable product innovation—is making a meaningful difference in patients’ lives. And there’s more to come.

Guided by our core values

Guided by our core values of patients, science and passion, we use our innovative technologies to fulfill our mission of developing new and potentially best-in-class therapies that address unmet medical needs.

NEWS RELEASES

June 9, 2025

TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial

June 2, 2025

FDA Accepts TransCon® CNP NDA for Priority Review

May 13, 2025

New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)

A pipeline with the potential to impact patient lives worldwide

We have three endocrinology rare disease product candidates in clinical development, and a pipeline of oncology candidates closely following.

Discover Our Pipeline

We are passionate about patients and science

We are a dynamic place to grow and learn with a unique global culture and entrepreneurial spirit.

You are about to access www.ascendispharma.com. Click below if you wish to proceed.

GO CANCEL

You are about to leave the Ascendis Pharma website and will continue on an external website. Ascendis Pharma takes no responsibility for the content of such external website.

GO CANCEL